Association of polymorphisms in oxidative stress genes with clinical outcomes for Bladder cancer treated with bacillus Calmette-Guérin

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Wei, Hua ^a   Kamat, Ashish ^a   Chen, Meng ^a   Ke, Hung Lung ^a   Chang, David W ^a   Yin, Jikai ^a   Grossman, H Barton ^a   Dinney, Colin P ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MICRORNA; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA GLYCOSYLTRANSFERASE; LUCIFERASE; NEIL2 PROTEIN, HUMAN; PRIMER DNA;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; NEIL2 GENE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLADDER TUMOR; CAUCASIAN; GENE LINKAGE DISEQUILIBRIUM; GENETICS; KAPLAN MEIER METHOD; OXIDATIVE STRESS; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

BCG VACCINE; DNA GLYCOSYLASES; DNA PRIMERS; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; LUCIFERASES; MALE; NEOPLASM RECURRENCE, LOCAL; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; TEXAS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84862192819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038533     Document Type: Article

References (26)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54: 303 314.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-465; discussion 475-467.
4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56: 430 442.
5. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41: 523 531.
6. Valavanidis A, Vlachogianni T, Fiotakis C, (2009) 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27: 120 139.
7. Mena S, Ortega A, Estrela JM, (2009) Oxidative stress in environmental-induced carcinogenesis. Mutat Res 674: 36 44.
8. Wellen KE, Thompson CB, (2010) Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 40: 323 332.
9. Ropolo M, Geroldi A, Degan P, Andreotti V, Zupo S, (2006) Accelerated repair and reduced mutagenicity of oxidative DNA damage in human bladder cells expressing the E. coli FPG protein. Int J Cancer 118: 1628 1634.
10. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472 482.
11. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, (2009) Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 15: 5258 5266.
12. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, (2008) Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 17: 2070 2077.
13. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, (2008) Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29: 2335 2340.
14. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, (2007) Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25: 3015 3023.
15. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G, (1994) Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 91: 9407 9411.
16. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, (2010) Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 3: 1235 1245.
17. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124 1129.
18. Yue P, Melamud E, Moult J, (2006) SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 7: 166.
19. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, (2009) Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30: 2047 2052.
20. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17: 2863 2873.
21. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, (2010) Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila).
22. Hazra TK, Kow YW, Hatahet Z, Imhoff B, Boldogh I, (2002) Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions. J Biol Chem 277: 30417 30420.
23. Kinslow CJ, El-Zein RA, Hill CE, Wickliffe JK, Abdel-Rahman SZ, (2008) Single nucleotide polymorphisms 5′ upstream the coding region of the NEIL2 gene influence gene transcription levels and alter levels of genetic damage. Genes Chromosomes Cancer 47: 923 932.
24. Kinslow CJ, El-Zein RA, Rondelli CM, Hill CE, Wickliffe JK, (2009) Regulatory regions responsive to oxidative stress in the promoter of the human DNA glycosylase gene NEIL2. Mutagenesis.
25. Bandaru V, Sunkara S, Wallace SS, Bond JP, (2002) A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to Escherichia coli endonuclease VIII. DNA Repair (Amst) 1: 517 529.
26. Pearl LH, (2000) Structure and function in the uracil-DNA glycosylase superfamily. Mutat Res 460: 165 181.